CTRI/2021/06/034325
Not yet recruiting
未知
Mid-cycle MRI to predict Complete Pathologic Response to Neoadjuvant chemotherapy in Breast cancer patients
Dr Smiti Sripathi Research Award For Breast Imaging Endowment Fund0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
- Sponsor
- Dr Smiti Sripathi Research Award For Breast Imaging Endowment Fund
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients diagnosed with Early breast cancer being treated with Neoadjuvant chemotherapy. Patients diagnosed with Locally advanced breast cancer, being treated with Neoadjuvant chemotherapy. Baseline and mid\-cycle MRI (taken after 3 cycles of chemotherapy) to be taken.
Exclusion Criteria
- •Patients with metastatic carcinoma of breast.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
MRI based prognostic biomarkers for treatment success of Minimal invasive treatment for Uterine Fibroids with Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU)leiomyomauterine fibroid10046828NL-OMON46077Isala Klinieken75
Not yet recruiting
Not Applicable
Magnetic resonance imaging predictors for relapsing Neuromyelitis OpticaMonophasic neuromyelitis Opticarelapses Neuromyelitis OpticaNeuromyelitis optica spectrumOptic NeuritisMagnetic Resonance Imaginganti-aquaporin 4 autoantibodyTCTR20240314003Rajavithi Hospital, Rangsit University90
Not yet recruiting
Not Applicable
EOPARD: Longitudinal Evaluation Of a Predictive Algorithm for Response in DepressioNL-OMON27632EUROSTARS80
Recruiting
Not Applicable
ongitudinal evaluation of an MRI-based predictive algorithm for early assessment of treatment response in depression (LEOPARD study)depressionMajor Depressive Disorder10027946NL-OMON55321Academisch Medisch Centrum80
Completed
Not Applicable
Whole-body MRI for initial staging, early response assessment and restaging after completion of therapy in pediatric Hodgkin lymphoma.Hodgkin lymphomalymph node cancer10025319NL-OMON41368niversitair Medisch Centrum Utrecht60